Fabiana Perrone

Fabiana Perrone

Auto-generated profile, based on publicly available information

Fabiana Perrone

Medical Oncology Unit, University Hospital of Parma, Parma, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
Sebastiano ButiSebastiano Buti
Sebastiano Buti
MBMelissa Bersanelli
Melissa Bersanelli
FPFabiana Perrone
Fabiana Perrone
SBSergio Bracarda
Sergio Bracarda
MMMassimo Di Maio
Massimo Di Maio
ACAlessio Cortellini
Alessio Cortellini

1 August 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
FPFabiana Perrone
Fabiana Perrone
LBLorenzo Belluomini
Lorenzo Belluomini
MMMarco Mazzotta
Marco Mazzotta
MBMaristella Bianconi
Maristella Bianconi
VNVincenzo Di Noia
Vincenzo Di Noia
SPSara Pilotto
Sara Pilotto

16 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FPFabiana Perrone
Fabiana Perrone
GMGiulia Mazzaschi
Giulia Mazzaschi
RMRoberta Minari
Roberta Minari
MVMichela Verzè
Michela Verzè
CACinzia Azzoni
Cinzia Azzoni
Marcello TiseoMarcello Tiseo
Marcello Tiseo
Introduction: BRAF mutation involved 2–4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations. Materials and Methods: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients. Results: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype. Conclusions: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.

13 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
GMGiulia Mazzaschi
Giulia Mazzaschi
CMCristina Marrocchio
Cristina Marrocchio
LTLucas Moron Dalla Tor
Lucas Moron Dalla Tor
LLLudovica Leo
Ludovica Leo
MBMaurizio Balbi
Maurizio Balbi
NSNicola Sverzellati
Nicola Sverzellati
Purpose: To uncover the underpinnings of acquired resistance (AR) to immunotherapy (IO), we determined whether distinctive clinicopathologic, radiomic, and peripheral blood (PB) immune-inflammatory features reflect oligo- and systemic (sys)-AR in patients with advanced non–small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor therapy. Experimental Design: On 105 consecutive patients with IO-treated advanced NSCLC, PB immunophenotypes, cytokines, and CT-derived radiomic features (RF), extracted from primary and merged metastatic lesions, were prospectively collected at baseline (T0) and at the first disease assessment (T1, 9–12 weeks), and their Δ variation [(T1−T0)/T0] was computed. AR, defined as progression after the initial response (complete/partial) or stable disease ≥6 months, was subdivided according to the number of new and/or progressive lesions in oligoAR (≤3) and sysAR (>3). Clinicopathologic, PB, and radiomic parameters and survival outcomes were statistically correlated to AR patterns. Results: OligoAR and sysAR involved 24% and 12.4% of cases, respectively. Whereas baseline PB immune profiles were comparable, a Δpos cytotoxic (NK, CD8+granzyme B+) and Δneg immunosuppressive (CD14+ monocytes) dynamic coupled with different modulations of IL-6, TGF-β1, TNFα, and soluble PD-L1 represented distinctive features of oligoAR versus sysAR (P < 0.05). Significantly longer postprogression survival characterized oligoAR versus sysAR (median 20.3 vs. 5.6 months; HR, 0.22; P < 0.001). The number and sites of oligoAR involvement appeared to condition the blood immune background (P < 0.05) and survival. ΔRFs outperformed baseline RFs, with 15 ΔRFs sharply discriminating oligoAR from sysAR (P range: <0.001–0.04). ROC analysis confirmed the optimal performance of top-ranked ΔRFs (AUC range: 0.88–0.99). Conclusions: Longitudinal analysis of blood-immune hallmarks and radiomic descriptors may decipher distinct patterns of AR to IO in advanced patients with NSCLC. See related commentary by Jeng and Schoenfeld, p. 1381

4 June 2024 in Cancer Letters
Verified
Journal Article
Open access
KFKylie Fletcher
Kylie Fletcher
ACAlessio Cortellini
Alessio Cortellini
TGTeja Ganta
Teja Ganta
RKRoma Kankaria
Roma Kankaria
HSHaocan Song
Haocan Song
DJDouglas B Johnson
Douglas B Johnson
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients >= 80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy. We determined response rate, overall survival (OS), and progression-free survival (PFS) in patients who discontinued therapy early (<12 months) for reasons other than progression or death. We used descriptive statistics for demographics, response, and toxicity rates. Survival statistics were described using Kaplan Meier curves. Median (range) age at anti-PD-1 initiation was 83.0 (75.8-97.0) years. The cancer types included were melanoma (n = 286), non-small cell lung cancer (NSCLC) (n = 345), urothelial cell carcinoma (UCC) (n = 108), and renal cell carcinoma (RCC) (n = 34). Of these, 102 met the primary endpoint of <12 months to discontinuation for reasons other than death or progression. Median PFS and OS, respectively, for these patients were 34.4 months and 46.6 months for melanoma, 15.8 months and 23.4 months for NSCLC, and 10.4 months and 15.8 months for UCC. This study suggests geriatric patients who have demonstrated therapeutic benefit and discontinued anti-PD-1 therapy at less than 12 months of duration for reasons other than progression may have durable clinical benefit without additional therapy.